FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310120334> ?p ?o ?g. }

• W4310120334 endingPage "5545" @default.
• W4310120334 startingPage "5543" @default.
• W4310120334 abstract "Introduction: Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count resulting from platelet destruction and impaired platelet production. In the last decades, thrombopoietin receptor agonists (TPO-RAs) demonstrated a high rate of response in ITP and are licensed for use in persistent or chronic patients who have had an insufficient response to first line treatment with corticosteroids or Intravenous Immunoglobulin (IVIG). Some evidence suggests that switching to the alternate TPO-RA can be an appealing treatment option in patients with ITP for efficacy or safety issues; however, much of the evidence is retrospective and only a few prospective studies investigating alternate use of TPO-RAs. Hetrombopag is the first small molecule, nonpeptide oral TPO-RA developed in China and its efficacy has been demonstrated in a multicenter phase III trial (NCT03222843). Here we conducted a post hoc analysis of this phase III trial to assess the response in patients who switched from eltrombopag to hetrombopag. Methods：A multicenter phase III study included a randomized, double-blind, placebo-controlled, 10-week treatment period (hetrombopag or placebo), sequentially followed by an open-label 14-week treatment period, during which patients who received placebo switched to eltrombopag with an initial dosage of 25 mg once daily and can be adjusted to a maximum of 75 mg once daily. Patients who completed eltrombopag 14-week treatment could directly continue additional 24-week hetrombopag treatment initiated at 2.5, 3.75, 5, or 7.5 mg once daily at the discretion of the investigator. Patients were assessed for efficacy and safety at every scheduled visit. In this post-hoc analysis, we investigated the response switching from eltrombopag to hetrombopag in ITP patients. Results: All 63 (74.1%) patients who completed the initial 24-week treatment (10-week placebo and 14-week eltrombopag) entered a prespecified additional 24-week hetrombopag treatment period. At enrollment, the median age was 43 years (range 18-70) and 47 (74.6%) patients were female, the duration of ITP was three years or longer in 40(63.5%) patients. The median baseline platelet count before switching to hetrombopag was 69.0×109/L (range 6.0-278.0×109/L ) and one third patients had not achieved a sustained response (platelet count≥50×109/L) after eltrombopag treatment. The median dose of the prior eltrombopag at the time of switching was 50 mg daily. As of data cutoff on November 19, 2020, 58 (92%) patients completed the hetrombopag treatment period, the median exposure to hetrombopag was 169.0 days (range, 53.0-176.0); 28 (44.4%) patients received the maximum dose of 7.5 mg once daily and the final dose of the other 16 (25.4 %) patients was 5 mg once daily. Overall, 56/63 (88.9%) achieved a platelet response (platelet count≥50×109/L) after switching from eltrombopag to hetrombopag. Among 12 patients with prior platelet count lower than 30×109/L, eight patients (66.7%) achieved response. For nine patients with prior platelet count between 30×109/L and 50×109/L, eight patients (88.9%) achieved response (Table 1). The median platelet count was 70 ×109/L after 2 weeks of switching and ranged between 62.5 ×109/L and 110 ×109/L across every scheduled visit during 24-week treatment with hetrombopag, highlighting that consistent platelet response could be maintained after switching from eltrombopag to hetrombopag. (Figure 1). The median maximum continuous duration of response was 78 days (range 8-165) and the median total duration of response was 104 days (range, 8-165) after switching to hetrombopag. In addition, 5(7.9%) patients received protocol-defined rescue therapy and 3(4.8%) patients had bleeding symptoms (All were grade 1 according to WHO bleeding scale) during hetrombopag treatment. Conclusion：In this one of the largest evaluations of switching between different TPO-RAs. Hetrombopag was effective following prior eltrombopag treatment, with high response rates even in patients with inadequate response to the prior therapy. Our results confirm the reported efficacy of TPO-RA switch in ITP patients and the lack of cross-resistance between the two available TPO-RAs. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310120334 created "2022-11-30" @default.
• W4310120334 creator A5001168093 @default.
• W4310120334 creator A5002329460 @default.
• W4310120334 creator A5003106627 @default.
• W4310120334 creator A5011125335 @default.
• W4310120334 creator A5013508493 @default.
• W4310120334 creator A5014198549 @default.
• W4310120334 creator A5016524884 @default.
• W4310120334 creator A5023342846 @default.
• W4310120334 creator A5029667848 @default.
• W4310120334 creator A5038805449 @default.
• W4310120334 creator A5040401360 @default.
• W4310120334 creator A5043052787 @default.
• W4310120334 creator A5045714102 @default.
• W4310120334 creator A5046409333 @default.
• W4310120334 creator A5048815633 @default.
• W4310120334 creator A5051832254 @default.
• W4310120334 creator A5053307277 @default.
• W4310120334 creator A5058808630 @default.
• W4310120334 creator A5063481044 @default.
• W4310120334 creator A5067997175 @default.
• W4310120334 creator A5068729755 @default.
• W4310120334 creator A5075906612 @default.
• W4310120334 creator A5077554678 @default.
• W4310120334 creator A5077666079 @default.
• W4310120334 creator A5080945746 @default.
• W4310120334 creator A5083211040 @default.
• W4310120334 creator A5084456685 @default.
• W4310120334 creator A5088192232 @default.
• W4310120334 creator A5091815974 @default.
• W4310120334 date "2022-11-15" @default.
• W4310120334 modified "2023-09-29" @default.
• W4310120334 title "Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial" @default.
• W4310120334 doi "https://doi.org/10.1182/blood-2022-162945" @default.
• W4310120334 hasPublicationYear "2022" @default.
• W4310120334 type Work @default.
• W4310120334 citedByCount "0" @default.
• W4310120334 crossrefType "journal-article" @default.
• W4310120334 hasAuthorship W4310120334A5001168093 @default.
• W4310120334 hasAuthorship W4310120334A5002329460 @default.
• W4310120334 hasAuthorship W4310120334A5003106627 @default.
• W4310120334 hasAuthorship W4310120334A5011125335 @default.
• W4310120334 hasAuthorship W4310120334A5013508493 @default.
• W4310120334 hasAuthorship W4310120334A5014198549 @default.
• W4310120334 hasAuthorship W4310120334A5016524884 @default.
• W4310120334 hasAuthorship W4310120334A5023342846 @default.
• W4310120334 hasAuthorship W4310120334A5029667848 @default.
• W4310120334 hasAuthorship W4310120334A5038805449 @default.
• W4310120334 hasAuthorship W4310120334A5040401360 @default.
• W4310120334 hasAuthorship W4310120334A5043052787 @default.
• W4310120334 hasAuthorship W4310120334A5045714102 @default.
• W4310120334 hasAuthorship W4310120334A5046409333 @default.
• W4310120334 hasAuthorship W4310120334A5048815633 @default.
• W4310120334 hasAuthorship W4310120334A5051832254 @default.
• W4310120334 hasAuthorship W4310120334A5053307277 @default.
• W4310120334 hasAuthorship W4310120334A5058808630 @default.
• W4310120334 hasAuthorship W4310120334A5063481044 @default.
• W4310120334 hasAuthorship W4310120334A5067997175 @default.
• W4310120334 hasAuthorship W4310120334A5068729755 @default.
• W4310120334 hasAuthorship W4310120334A5075906612 @default.
• W4310120334 hasAuthorship W4310120334A5077554678 @default.
• W4310120334 hasAuthorship W4310120334A5077666079 @default.
• W4310120334 hasAuthorship W4310120334A5080945746 @default.
• W4310120334 hasAuthorship W4310120334A5083211040 @default.
• W4310120334 hasAuthorship W4310120334A5084456685 @default.
• W4310120334 hasAuthorship W4310120334A5088192232 @default.
• W4310120334 hasAuthorship W4310120334A5091815974 @default.
• W4310120334 hasConcept C109159458 @default.
• W4310120334 hasConcept C126322002 @default.
• W4310120334 hasConcept C168563851 @default.
• W4310120334 hasConcept C187212893 @default.
• W4310120334 hasConcept C202953159 @default.
• W4310120334 hasConcept C2776915898 @default.
• W4310120334 hasConcept C2777863708 @default.
• W4310120334 hasConcept C2780588981 @default.
• W4310120334 hasConcept C28328180 @default.
• W4310120334 hasConcept C2992886853 @default.
• W4310120334 hasConcept C2993327898 @default.
• W4310120334 hasConcept C54355233 @default.
• W4310120334 hasConcept C67761136 @default.
• W4310120334 hasConcept C71924100 @default.
• W4310120334 hasConcept C86803240 @default.
• W4310120334 hasConcept C89560881 @default.
• W4310120334 hasConceptScore W4310120334C109159458 @default.
• W4310120334 hasConceptScore W4310120334C126322002 @default.
• W4310120334 hasConceptScore W4310120334C168563851 @default.
• W4310120334 hasConceptScore W4310120334C187212893 @default.
• W4310120334 hasConceptScore W4310120334C202953159 @default.
• W4310120334 hasConceptScore W4310120334C2776915898 @default.
• W4310120334 hasConceptScore W4310120334C2777863708 @default.
• W4310120334 hasConceptScore W4310120334C2780588981 @default.
• W4310120334 hasConceptScore W4310120334C28328180 @default.
• W4310120334 hasConceptScore W4310120334C2992886853 @default.
• W4310120334 hasConceptScore W4310120334C2993327898 @default.
• W4310120334 hasConceptScore W4310120334C54355233 @default.
• W4310120334 hasConceptScore W4310120334C67761136 @default.
• W4310120334 hasConceptScore W4310120334C71924100 @default.

• next